BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS
Steg P, Mehran R, Goldstein P, Witzenbichler B, Hof A, Guagliumi G, Hamm C, Genereux P, Clemmensen P, Parise H, Pocock S, Gersh B, Bernstein D, Deliargyris E, Stone G, Bichat H. BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS. Journal Of The American College Of Cardiology 2014, 63: a34. DOI: 10.1016/s0735-1097(14)60034-6.Peer-Reviewed Original ResearchImpact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus Analysis From 18 Pooled Randomized Trials
Kedhi E, Généreux P, Palmerini T, McAndrew T, Parise H, Mehran R, Dangas G, Stone G. Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus Analysis From 18 Pooled Randomized Trials. Journal Of The American College Of Cardiology 2014, 63: 2111-2118. PMID: 24632279, DOI: 10.1016/j.jacc.2014.01.064.Peer-Reviewed Original ResearchConceptsDiabetes mellitusRepeat revascularizationMyocardial infarctionLesion complexityStent outcomesCardiac deathType A/B1 lesionsType B2/C lesionsB2/C lesionsPropensity score-matched groupsCoronary lesion complexityTarget vessel revascularizationPatient-level dataB1 lesionsNoncomplex lesionsVessel revascularizationDiabetic statusC lesionsDES eraRandomized trialsRisk factorsTarget lesionsDES safetyTreatment outcomesBaseline differences